GlassScriptPhysician profile
Maliha Abbas
NPI 1174963920
$1,362.38
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $17.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $329.33 | 2019 | |
| Pfizer INC. | $178.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $133.52 | 2019 | |
| Novo Nordisk INC | $123.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.89 | 2019 | |
| Amgen INC. | $71.32 | 2019 | |
| Glaxosmithkline, LLC. | $71.26 | 2019 | |
| Abbott Laboratories | $59.53 | 2019 | |
| Ironshore Pharmaceuticals INC. | $50.34 | 2019 | |
| Merck Sharp & Dohme LLC | $41.75 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $41.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.83 | 2019 | |
| Shire North American Group INC | $31.36 | 2019 | |
| Astellas Pharma US INC | $21.68 | 2019 | |
| Tandem Diabetes Care, INC. | $21.46 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $19.14 | 2019 | |
| Adlon Therapeutics L.P. | $15.74 | 2019 | |
| Currax Pharmaceuticals LLC | $13.64 | 2019 | |
| Allergan, INC. | $12.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maliha Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.